My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
RES-2022-168
>
Meetings
>
2022
>
09. September
>
2022-09-06 10:00 AM - Commissioners' Agenda
>
RES-2022-168
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
9/13/2022 11:54:56 AM
Creation date
9/13/2022 11:53:49 AM
Metadata
Fields
Template:
Meeting
Date
9/6/2022
Meeting title
Commissioners' Agenda
Location
Commissioners' Auditorium
Address
205 West 5th Room 109 - Ellensburg
Meeting type
Regular
Meeting document type
Fully Executed Version
Supplemental fields
Item
Request to Approve a Resolution Authorizing the Chair's Signature on a Opioid Litigation Allocation Agreement
Order
3
Placement
Consent Agenda
Row ID
93293
Type
Agreement
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
107
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
or overdose fatality), and training of health care personnel to identify and address such <br />trauma <br />7. Support detoxification (detox) and withdrawal management services for persons with <br />OUD and any co-occurring SUD/MH conditions, co-usage, and/or co-addiction, <br />including medical detox, referral to treatment, or connections to other services or <br />supports. <br />8. Support training on MAT for health care providers, students, or other supporting <br />professionals, such as peer recovery coaches or recovery outreach specialists, <br />including telementoring to assist community-based providers in rural or underserved <br />areas. <br />9. Support workforce development for addiction professionals who work with persons <br />with OUD and any co-occurring SUD/MH conditions, co-usage, andlor co-addiction. <br />10. Provide fellowships for addiction medicine specialists for direct patient care, <br />instructors, and clinical research for treatments. <br />1 1. Provide funding and training for clinicians to obtain a waiver under the federal Drug <br />Addiction Treatment Act of 2000 (DATA 2000) to prescribe MAT for OUD, and <br />provide technical assistance and professional support to clinicians who have obtained <br />a DATA 2000 waiver. <br />12. Support the dissemination of web-based training curricula, such as the American <br />Academy of Addiction Psychiatry's Provider Clinical Support Service-Opioids web- <br />based training curriculum and motivational interviewing. <br />13. Support the development and dissemination of new curricula, such as the American <br />Academy of Addiction Psychiatry's Provider Clinical Support Service for <br />Medication-Assisted Treatment. <br />B. SUPPORT PEOPLE IN TREATMENT AND RE,COVERY <br />Support people in treatment for and recovery from OUD and any co-occurring SUD/MH <br />conditions, co-usage, andlor co-addiction through evidence-based, evidence-informed, or <br />promising programs or strategies that may include, but are not limited to, the following: <br />I . Provide the full continuum of care of recovery services for OUD and any co-occurring <br />SUD/MH conditions, co-usage, andlor co-addiction, including supportive housing, <br />residential treatment, medical detox services, peer support services and counseling, <br />community navigators, case management, and connections to community-based <br />services. <br />2. Provide counseling, peer-support, recovery case management and residential <br />treatment with access to medications for those who need it to persons with OUD and <br />any co-occurring SUD/MH conditions, co-usage, andlor co-addiction. <br />2
The URL can be used to link to this page
Your browser does not support the video tag.